Why the study?
Vericiguat improves clinical outcomes in HFrEF trials, but real-world evidence on its effectiveness outside controlled research settings remains limited.
Does vericiguat reduce cardiac mortality and hospitalization for HF in Chinese patients with symptomatic heart failure and LVEF <45%?
Does vericiguat reduce cardiac mortality and hospitalization for HF in Chinese patients with symptomatic heart failure and LVEF <45%?
Real-world data from a Chinese cohort demonstrates that vericiguat is associated with reduced cardiac mortality and heart failure hospitalizations in patients with HFrEF.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for post-discharge use in Chinese HFrEF; extends VICTORIA to real-world practice but leaves confounding unaddressed.
Zhou et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: